Absolute CD3 + T‐Cell Counts After Anti‐Thymocyte Globulin: Impact on Graft and Infectious Outcomes in Pediatric Kidney Recipients
Pediatric Transplantation · 2025
DOI: 10.1111/petr.70141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, 2025. Verfasst von Travis Churilla und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Nephrology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Antilymphocyte Serum, Kidney Transplantation, CD3 Complex, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Rabbit anti‐thymocyte globulin (r‐ATG) is a thymocyte depleting agent for the induction of immunosuppression in kidney transplant recipients (KTRs). There is little data comparing a level of CD3+ T‐cell suppression for optimal graft outcomes with minimized infectious risk.
Methods
KTRs from January 2020 to January 2024 were included if they met these criteria: (1) < 21 years of age at transplantation, (2) no previous receipt of a solid organ or hematopoietic stem cell transplant, (3) completion of a r‐ATG‐based induction protocol, (4) had absolute CD3+ T‐cell counts quantified at induction, and (5) at least 6 months posttransplant follow‐up. Patients were grouped based on their CD3+ cell counts during or within 24‐h of induction (< 25 cells/mm 3 vs. ≥ 25 cells/mm 3 ) and statistical comparisons were made.
Results
Of 111 KTRs reviewed, 28 were included. A CD3+ cell count < 25 was achieved in 22/28 (79%) recipients, following a median r‐ATG dose of 4.35 mg/kg (IQR: 3.00–4.55). The median age was 15 years (IQR: 13.50–16.75). The median dose of r‐ATG administered by completion of induction was 4.530 mg/kg (IQR: 4.434–4.737) and did not differ between groups ( p = 0.758). There was no difference in the rate of rejection, infectious markers, or hospitalization based on CD3+ levels. There was no mortality or graft loss.
Conclusions
There were no observed differences in post‐transplant outcomes when compared by CD3+. As the dose of r‐ATG delivered and outcomes were similar, monitoring of CD3+ T‐cell populations during induction may not be necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Nephrology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
- Department of Pharmacy, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
ORCID-Profile: Travis Churilla, Natalia Panek, Priya S Verghese
Zitieren
APA
Churilla, T., Panek, N., & Verghese, P. S. (2025). Absolute CD3 + T‐Cell Counts After Anti‐Thymocyte Globulin: Impact on Graft and Infectious Outcomes in Pediatric Kidney Recipients. Pediatric Transplantation. https://doi.org/10.1111/petr.70141
Vancouver
Churilla T, Panek N, Verghese PS. Absolute CD3 + T‐Cell Counts After Anti‐Thymocyte Globulin: Impact on Graft and Infectious Outcomes in Pediatric Kidney Recipients. Pediatric Transplantation. 2025. doi:10.1111/petr.70141
BibTeX
@article{Churilla2025,
author = {Churilla, Travis and Panek, Natalia and Verghese, Priya S},
title = {Absolute CD3 + T‐Cell Counts After Anti‐Thymocyte Globulin: Impact on Graft and Infectious Outcomes in Pediatric Kidney Recipients},
journal = {Pediatric Transplantation},
year = {2025},
doi = {10.1111/petr.70141}
}
EUVIMED